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Abstract 1 
 2 
Background: Cancer-Associated thrombosis is common. Recommended treatment is daily injected 3 
low-molecular-weight heparin for 6months. Most studies focus on prophylaxis and treatment; few 4 
have explored patients’ experience.   5 
Aims  6 
To identify and synthesise the available literature concerning patients’ experience of cancer 7 
associated thrombosis.   8 
 9 
Design 10 
 Systematic literature review and qualitative thematic synthesis.  11 
Methods 12 
MEDLINE, Embase, CINAHL, PsychINFO (until 10/2016; limited to English) were searched. Eligible 13 
papers were qualitative studies of adult patients’ experience of cancer-associated thrombosis. Two 14 
researchers screened titles/abstracts/papers against inclusion criteria with recourse to a third for 15 
disagreements. Critical Appraisal Skills Programme qualitative checklist tool was used for quality 16 
appraisal.  17 
 18 
Results 19 
1397 articles were identified. Five qualitative studies (total n=92; age range 32 to 84 years) met the 20 
inclusion criteria. Participants had various cancer types. Most had advanced disease and were 21 
receiving palliative care. Four major themes emerged from the data: knowledge deficit (patients and 22 
clinicians); effects of cancer associated thrombosis (physical and psychological); effects of 23 
anticoagulation; coping strategies.  24 
 25 
Conclusion 26 
The cancer journey is difficult in itself, but thrombosis was an additional, frightening and unexpected 27 
burden. Although the association between cancer and thromboembolism is well known, cancer 28 
patients are not educated routinely about the risk or warning symptoms/signs of thromboembolism 29 
which may otherwise be misattributed to the cancer by patient and clinician alike.     This systematic 30 
review highlights the impact of cancer-associated thrombosis on the lives of cancer patients, and 31 
calls for education for patients and clinicians to be part of routine care, and further work to address 32 
this patient priority 33 
 34 
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INTRODUCTION 1 
Venous thromboembolism  is a life changing diagnosis. Comprising deep vein thrombosis  and 2 
pulmonary embolus  it is a common phenomenon worldwide. It affects one in 1,000 patients; 6.5 3 
million people globally each year(1, 2). The risk of venous thromboembolism increases by 6-7 folds in 4 
patients with cancer compared with non-cancer patients (3, 4). Approximately 20% of all newly 5 
diagnosed cases of venous thromboembolism are cancer patients (5), and post-mortem studies have 6 
demonstrated rates of  venous thromboembolism in patients with cancer to be as high as 50%(6) 7 
Up to 20% of patients with malignancy will develop cancer-associated thrombosis (5) 8 
Although the risk increases with late-stage and during chemotherapy, over 50% of  occurs during the 9 
first three months from diagnosis(3) and interferes with cancer management(6). 10 
International guidelines for the treatment of cancer-associated thrombosis recommend 11 
anticoagulation with weight-adjusted low-molecular-weight heparin  for 3–6 months. (7-9) However, 12 
even with an optimal anticoagulation, cancer-associated thrombosis is associated with a higher 13 
recurrence rate than non-cancer venous thrombosis, and a poorer prognosis than cancer patients 14 
without thrombosis.(10-12) 15 
Apart from conferring a worse prognosis, the diagnosis of venous thromboembolism is a physically 16 
and emotionally distressing phenomenon that affects patients’ experience and quality of life (13, 14). 17 
However, data available on how cancer associated thrombosis and its treatment affect the cancer 18 
patients’ experience is scarce compared with that in relation to treatment or prevention. 19 
Systematic reviews and meta-analysis on cancer associated thrombosis are limited to biomolecular 20 
markers associated with cancer associated thrombosis (15, 16) risk assessment of venous 21 
thromboembolism in cancer patients(17, 18) or both (19), clinical outcome, thromboprophylaxis,(20) 22 
management (21-23) and risk stratification.(24)  23 
  24 
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In order to improve our understanding and raise awareness of cancer associated thrombosis and to 1 
stimulate improvements in the supportive care of cancer patients, we undertook a systematic 2 
literature review to answer the following question, “ what is the experience of people living with 3 
cancer associated thrombosis? 4 
 5 
METHODS 6 
Search strategy 7 
Two independent researchers conducted the search (NB, WI).  MeSH terms and text words for 8 
cancer, venous thromboembolism and quality of life (see supplementary Table 1) were combined. 9 
The following electronic databases were searched: Embase, MEDLINE, CINAHL, and PsychINFO, until 10 
October 2016 and limited to English language, according to a pre-constructed protocol. In addition 11 
an online search was performed for the following journals:  Journal of Thrombosis Hemostasis 12 
(ISTH/JTH), Thrombosis Research and Hematologica. Bibliographies from relevant articles were 13 
examined for further related studies.  14 
Inclusion criteria  15 
 16 
 Studies of adult cancer patients with venous thromboembolism with or without treatment for the 17 
venous thromboembolism were included. The review included qualitative studies that assessed the 18 
quality of life or experience of this group of patients. 19 
Study selection 20 
 21 
The titles, abstracts and full studies were screened by two independent researchers (NB, WI) against 22 
the inclusion criteria. Disagreement was resolved by discussion with access to a third opinion (MJ).  23 
Studies that matched the selection criteria were retrieved and their full text version analysed.   24 
25 
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Data extraction 1 
Data were extracted by NB; demographics of the included papers (author, year, design, population, 2 
question, main findings) and the primary quotations presented in the results. 3 
Quality Appraisal 4 
All articles were assessed against the Critical Appraisal Skills Programme (CASP) checklist tool for 5 
qualitative studies by NB and WI independently (25). Studies were not excluded on the basis of 6 
quality, but the assessment of quality was taken into account during analysis. 7 
Analysis 8 
The primary quotation data were synthesised by NB using thematic synthesis (26) and the principles 9 
of thematic analysis to explore the understanding of long term effects of venous thromboembolism 10 
on cancer patient’s life quality(27). This allows the context of each study to be taken into account 11 
whilst aiming to produce a generalizable synthesis(28). Direct quotes from patients and the 12 
researcher comments under the headings “results, findings, or discussion” from each study were 13 
extracted for coding. 14 
Thematic synthesis involved: line by line coding of the findings of primary articles after reading and 15 
rereading of the papers to get familiarised with the data included, then the codes were discussed 16 
with MJ, and a coding framework formed which was used to code all papers followed by 17 
development of descriptive and analytical themes from the codes, in discussion with MJ and JS (29). 18 
Both inductive (allowing themes to arise from the specific observations) and deductive (working 19 
within existing knowledge about the effect of venous thromboembolism on people without cancer, 20 
looking specifically within our data for similarities and differences) processes were involved. 21 
RESULTS 22 
Overview of articles 23 
The search identified a total 13197 articles, Embase (11632); MEDLINE (1272); CINAHL (254); and 24 
PsycINFO (38) articles. One additional article was identified through searches of relevant 25 
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bibliographies.  Eleven full articles were retrieved and assessed for eligibility; six articles were 1 
excluded following review. This is summarised in the PRISMA flow diagram (Figure 1). 2 
Five qualitative studies published between 2005 and 2015, met the inclusion criteria. Four of them 3 
were conducted in the UK. The key characteristics of the studies are summarised in Table 1. 4 
 Study populations 5 
A total of 92 cancer patients with venous thromboembolism were included in these studies. All were 6 
adult patients of mixed gender with mean age of 58 years (range 32-84). Participants represent a 7 
wide variety of cancer types and stage.  The most cancers were: breast, colorectal, ovary, lung, 8 
prostate, pancreas, and renal.  9 
  10 
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Figure 1: (PRISMA) Flow diagram 3 
 4 
 5 
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Themes 1 
Four major themes were identified: knowledge deficit, the effects ofcancer associated thrombosis 2 
(physical and psychological effects), the effects of cancer associated thrombosis treatments, and 3 
coping strategies. 4 
Knowledge deficit 5 
Two studies investigated the patients’ knowledge about cancer associated thrombosis in the context 6 
of cancer journey(13, 30) 7 
Despite the fact that cancer associated thrombosis may develop as early as the first few months of 8 
diagnosis of cancer, and that the risk is increased with cancer treatments (chemotherapy, surgery, 9 
and hospitalisation), and disease progression participants were often not aware of their increased 10 
risk or of the warning symptoms of cancer associated thrombosis. 11 
“During my cancer treatments, I was never told that there was a risk of getting a blood clot. I didn’t 12 
know about it… I was pretty shaken up”(30) 13 
“ I have never heard of venous thromboembolism, so that’s why I was so shocked”(30) 14 
“[…] but they don’t tell you you’re gonna get clots after chemo, that’s the one thing they haven’t, 15 
they never said but we, we just put it down to, it’s just my breathing […] just that one item of 16 
information that we weren’t aware of”. [VCC07](13) 17 
Moreover, patients on chemotherapy usually experienced different side effects, when they develop 18 
a venous thromboembolism they associate it with chemotherapy and do not recognise that their 19 
symptoms are symptoms of a venous thromboembolism. 20 
“[…] but um this time again first set of chemo, she felt terrible and the thing is, when we went back to 21 
hospital really desperate, the only problem we thought was that it was the chemotherapy that was 22 
causing it”. [RG02](13) 23 
10 
 
  1 
11 
 
On other hand participants with prior knowledge about venous thromboembolism respond in calm 1 
and seek medical help immediately. 2 
“I was out of breath and I said to my partner, ‘I think we are going to hospital’ without panic because 3 
I knew that it was something that could be rectified effectively)(30)  4 
There was also evidence of limited awareness about venous thromboembolism and cancer amongst 5 
health care professionals (13) . This is consistent with patient reports of delayed diagnosis of the 6 
venous thromboembolism; on many occasions alternative causes were considered first. 7 
 “It just got bigger and bigger and bigger, over months really […] then they doubled them (diuretics), 8 
and then they trebled them”. [RG05].(13) 9 
 10 
Effects of cancer associated thrombosis 11 
The effects of cancer associated thrombosis theme include three subthemes (responses to venous 12 
thromboembolism diagnosis, psychological and physical effects). 13 
Effects of diagnosis process  14 
Patients’ perspective on cancer associated thrombosis diagnosis varied. Some participants reacted to 15 
the diagnosis of cancer associated thrombosis as an entity distinct to the cancer, while others 16 
considered cancer associated thrombosis as a complication of their cancer. However, in both cases 17 
the diagnosis of cancer associated thrombosis had a negative impact; it led to delays in cancer 18 
treatment and added more burden to their health. 19 
“Having the cancer and then the thrombosis on top of it, not knowing how bad it was”(13)  20 
 “The fact that there were clots meant we couldn’t operate on my leg. Not being able to operate my 21 
leg pushed back my radiation and chemotherapy. So everything was shifted in time”(30)   22 
12 
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Psychological effects 1 
 2 
Four studies reported that the diagnosis of cancer associated thrombosis was distressing, especially 3 
in those without prior knowledge of the symptoms, had a major impact on patients’ lives and was 4 
perceived as life threatening (13, 30-32) 5 
“PE is not cancer but it’s dangerous too, because with both you are playing with your life”(30) 6 
“I felt I was having a heart attack….that stress made (the symptoms) worse”(30). 7 
 “[…] having the cancer and then the thrombosis on top of it, erm, not knowing how bad it was when I 8 
went in, I know I was in terrific pain with my chest and that erm, it was frightening to be honest. 9 
[VCC01]”(13)  10 
“It frightened the life out of me, I was more scared of that than the cancer. You know blood clots can 11 
kill you like that (clicks fingers), cancer you’ve got a little bit of chance, you know. [PT13]”(31) 12 
The response to the diagnosis was less stressful among participants with previous experience of 13 
venous thromboembolism who reported being calm and not shocked. 14 
“Knowing [that it is a PE] reassures you a little, nevertheless. . . I knew I need to go to the hospital as 15 
fast as possible”(30)   16 
“Would er the main thing that did it was erm apprehension basically about er the clot and if a clot 17 
does occur it hits you like that bang” (Interview NC5)(32) 18 
 19 
Physical Effects 20 
 21 
The acute and chronic symptoms of cancer associated thrombosis were profound and negatively 22 
affected patients’ lives. Mockler 2012 and Seaman 2014 described the negative impact of symptoms 23 
that interfered with patients’ daily living(30, 31). 24 
In particular participants with PE described that being short of breath prevented them from  25 
14 
 
completing even small tasks at home. Symptoms from cancer associated thrombosis prevented them 1 
from returning to normal life and activities; unable to do daily activities around the house or to 2 
mobilize unaided. 3 
“I cannot do anything…will I always continue heading in this regression”(30) 4 
“The lack of energy and being out of breath….it’s just so frustrating …Frustration of not being able to 5 
be where I should be, in my mind”(30) 6 
“I couldn’t breathe; I literally couldn’t breathe and couldn’t talk. [PT6]”(31) 7 
“I was very breathless, even bending down to the washing machine to put a wash in I was gasping for 8 
air. [PT11](31) 9 
 10 
Effects of venous thromboembolism treatments 11 
 12 
This theme captured patients’ experience of anticoagulation treatment (self-injected weight-13 
adjusted Low molecular weight heparin, warfarin and direct oral anticoagulants). Four studies 14 
assessed patients’ responses to anticoagulation focusing on the acceptability of Low molecular 15 
weight heparin (30-33) It was clear that the treatment had a positive effect on patients’ life, 16 
especially, for those who had experienced distressing symptoms. 17 
 Most participants were started on Low molecular weight heparin and others had been on warfarin 18 
but changed to Low molecular weight heparin due to absorption difficulties, uncontrolled INR and/or 19 
venous thromboembolism recurrence. There was a general agreement by patients that Low 20 
molecular weight heparin was acceptable treatment and better than warfarin where comparison was 21 
possible. Self-injected Low molecular weight heparin allowed more self-control over their life and 22 
more freedom. However, this benefit was not without compromise, as side effects of bruising and 23 
injection-site lumps were common.   24 
“The heparin is so much simpler than all the ****ing about with warfarin' (22CS)” (33) 25 
15 
 
 “I really don’t feel like pricking myself, but if it’s that or dying well I’d rather prick myself”(30). 1 
  2 
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“I used to spend my life travelling to hospital for a warfarin check ... sat in the car ... sat in the waiting 1 
room ... not much of a life really” (19CS) (33) 2 
 “With the warfarin, what was kind of crappy was that I had to do blood tests every two weeks. But 3 
with Low molecular weight heparin no need for draws” (30) 4 
“I’m using the tops of my legs now so it isn’t as painful. I was using my stomach but after a while your 5 
stomach gets really hard and then you’ve got to really force them in”. [PT8](31) 6 
Those with advanced disease felt that treatment of their cancer associated thrombosis with optimal 7 
anticoagulation meant that their doctors did not give up on them, influencing their optimism and 8 
expectation of their doctors. 9 
“I know I'm going to die. I know that the doctors don't have any more chemo to give ... you don't like 10 
feeling that you've been put on the scrap heap ... the injection isn't stopping the cancer but it is 11 
stopping the blood clots” (14CS)(33)  12 
“It is important to know that people are still doing something”(15C)  (33) 13 
Some patients wish to take Low molecular weight heparin for longer than 6 months as long because 14 
of the continued risk and the peace of mind they felt with ongoing anticoagulation. This is expressed 15 
clearly by a patient in ALICAT study where views were sought on being randomised to continuation 16 
or cessation. 17 
“The thing that bothered me at that time was that I’d already had two episodes of of a blood clot and 18 
I thought if I was in the group that didn’t have the medication um there was a good chance that I’d 19 
I’d have another one and it could could have a lot more serious repercussions than if I just continued 20 
to take this medication”. (Interview NC3)(32) 21 
 “Um I thought no I think I’ll carry on rather than, you know, spending another day in hospital being 22 
prodded and probed like I was last time”. (Inerview NC2)(32) 23 
However; some patients wanted to stop Low molecular weight heparin injection after 6 months 24 
because of the side effects of the injections and others wanted to restore their normal life without 25 
injections. 26 
“  I was just happy to get off of it to be honest with you, um it was more or less the same time every 27 
17 
 
night, um and the pain as I said eh to me was terrible, horrific and a lot of bruising and things” 1 
(Interview NC1)(32) 2 
“And so I was very keen I have to say, I was predisposed I don’t want any further injections once the 3 
treatments finished I just want to try to get back to as much normality as I can”. (Interview NC8)(32) 4 
 5 
Employment of coping mechanisms 6 
 7 
It was clear that the response to the dual diagnosis of cancer and cancer associated thrombosis was 8 
very individual, with some  regarding it as a greater shock than their cancer, particularly among 9 
patients who considered cancer associated thrombosis as a setback on the road to cancer recovery, 10 
and others viewing it as less significant in comparison with their cancer (30). 11 
“I never broke down when I was told about the cancer […] I had the operation, went on the chemo, 12 
everything. The only time I broke down was when I went back in hospital when they told me I had 13 
blood clots […] the cancer to a point they can treat, hold it back – blood clots they go so quick and 14 
that frightened me, it was the only time I broke down”. [PT13](31) 15 
“During chemotherapy, I didn’t have any great nausea, and brachytherapy went well too. So I told 16 
myself, “Well, I’m going to overcome the cancer but No! Then I started to go down again”.(30) 17 
 The  employment of coping mechanisms theme illustrated ways that patients developed to move on 18 
with their lives. The treatment of venous thromboembolism brings with it symptomatic relief, 19 
reassuring patients that their condition is improving. This reduces distress and allows patients, over 20 
time, to get back to ‘some sort of normality’(13). Participants described the development of strict 21 
routines and rituals to ensure Low molecular weight heparin was administered on time and without 22 
fail.(31) 23 
“I usually take them between 8 and half past 8. And then I know it’s done, and I don’t forget for the 24 
day, then, because someone I was talking to, he was saying “You don’t do it in the night, do you?” 25 
and I said, “No, I get up, have my cup of tea then 8, half past 8 do it.” [PT13](31) 26 
18 
 
“[…] is a ritual now”. [VCC10](13)  1 
DISCUSSION 2 
The cancer journey is difficult in itself, but thrombosis was an additional, frightening and unexpected 3 
burden.  The association between cancer and venous thromboembolism was first reported in the 4 
19th century(34).  However, cancer patients are still not routinely educated about the risk or warning 5 
symptoms/signs of venous thromboembolism which may otherwise be misattributed to the cancer 6 
by patient and clinician alike.     7 
This systematic review highlights the impact of C cancer associated thrombosis AT on the lives of 8 
cancer patients, and calls for education for patients and clinicians to be part of routine care, and 9 
further work to address this patient priority. 10 
The four themes from this synthesis of primary qualitative studies (knowledge deficit, effects of 11 
cancer associated thrombosis, effects of anticoagulation, and employment of coping mechanisms) 12 
illustrate the ways in which cancer associated thrombosis affects quality of life. Thrombosis with its 13 
complex presentation, diagnosis and treatment, was seen  14 
by many patients as a significant additional, frightening and unexpected burden affecting cancer 15 
treatment and which impose psychosocial and functional limitations.   16 
 17 
Lack of knowledge of cancer associated thrombosis 18 
A survey of cancer patients found a better level of knowledge of cancer associated thrombosis risk 19 
than those in this review, but still half (53%) of participants were unaware of the increased risk of 20 
cancer associated thrombosis although three quarters knew that venous thromboembolism can be 21 
prevented.(35)  22 
19 
 
Eventhough the cancer associated thrombosis is not a new phenomenon, a lack of clinician 1 
awareness of cancer associated thrombosis appears to compound the lack of patient knowledge (36, 2 
37). In a study of 18 patients who had had venous thromboembolism, (not cancer-related), 3 
misdiagnosis and diagnostic delay made patients feel angry and distrustful of their medical team.(38) 4 
However, similar to Mockler’s study of people with cancer associated thrombosis, patients with a 5 
previous history of venous thromboembolism were less distressed, having recognised the symptoms 6 
and sought medical help more quickly (30).  7 
This lack of routine information giving is in contrast to other cancer-related complications such as 8 
malignant spinal cord compression and post chemotherapy neutropenia, where guidelines are 9 
systematically applied for patients and their family, and carers. Education includes the symptoms 10 
and signs to look for, when to seek medical help, and who to contact (39, 40). 11 
Inadequate information-giving is not new (41). However, people with venous thromboembolism 12 
appear clear about the degree of information they need including understanding their diagnosis, 13 
what they should do/ do not from diagnosis and with treatment (42). Information needs are 14 
individual and vary by gender, age and stage of disease; some wishing for full details; others want 15 
basic information only (43).  16 
 17 
 18 
Psychological burden 19 
The long-term outcomes following acute venous thromboembolism extend beyond the physical 20 
burden (44, 45) and the experience of symptomatic pulmonary embolism is a life-changing, 21 
distressing and frightening event (42).  Similar psychological effects were seen in this review, but in 22 
addition, cancer patients have to process this event in the context of the underlying cancer. For 23 
some, the potential of cancer associated thrombosis as a sudden killer came as a great shock, 24 
especially those who had viewed their cancer as a chronic illness.  25 
20 
 
 1 
Effects of cancer associated thrombosis treatment 2 
Seaman et al found that efficacy of treatment was paramount despite the hypothetical preference of 3 
a tablet over an injection(31). This finding was also highlighted in the study by Noble et al(46), where 4 
patients were concerned about safety, efficacy, and lack of interference with anticancer therapies 5 
ahead of method of administration. Patients in this review included those with advanced disease, 6 
but despite previously stated concerns about patient burden with Low molecular weight heparin 7 
(47), the use of Low molecular weight heparin was acceptable. The daily injections of precalculated 8 
dose of Low molecular weight heparin giving more control than the blood tests and dose alterations 9 
of warfarin.   10 
  11 
Employment of coping mechanisms 12 
Patients tried to maintain a sort of normality in everyday life consistent with previous findings that 13 
cancer patients find ways to minimize the impact of the side effects of cancer in their new life 14 
situation. (45)  15 
Education and support is important with regard to coping. One of the earliest reported educational 16 
group programmes for people with cancer was the ‘I Can Cope’ (ICC) programme (48). This has been 17 
well evaluated showing reduced anxiety, improved disease-related knowledge and sense of 18 
meaning(49)  19 
Uncertainty and information 20 
The varying responses to the threat of cancer associated thrombosis and its treatment seem to be 21 
related to uncertainty as to whether the cancer associated thrombosis will recur, whether it will 22 
resolve, whether the treatment will be effective and/or harmful. Uncertainty management 23 
theory(50, 51)  is one theoretical framework to help the understanding of how patients encounter, 24 
21 
 
appraise levels of danger, seek information, respond to and cope with health-related threats. The 1 
differing needs for information, ways of seeking it and success in receiving it are seen within these 2 
data presented. Likewise, some patients appraised the cancer associated thrombosis as very 3 
dangerous, whereas others (often those with previous experience and better information) were able 4 
to appraise it as less dangerous because they knew what to look for and how to act. Whilst the 5 
relationship between uncertainty and danger appraisal is complex, tailored and accessible 6 
information seems to play a key part in reducing anxiety even if absolute reassurances cannot be 7 
given(52, 53).  As Brashers states, uncertainty occurs when, “information is unavailable or 8 
inconsistent; and when people feel insecure in their own state of knowledge or the state of 9 
knowledge in general” (50). 10 
Strengths and limitations 11 
As with any systematic review it is possible to miss relevant studies. The included studies were 12 
qualitative research which is designed to give insights from the patients involved rather than to be 13 
generalizable. However through synthesis more generalizable findings can be derived(26). Only one 14 
included study came from outside the UK, however, they were from different centres, but still 15 
indicated similar concerns. 16 
Only limited papers were found, illustrating that this area has been under-researched. The serious 17 
concerns highlighted by this review show that further work is needed. 18 
 19 
Implications for clinical practice and policy makers 20 
Raised clinical awareness and the provision of basic information for patients about the risk of cancer 21 
associated thrombosis is a policy priority in the UK.(54) Information about cancer associated 22 
thrombosis, both written and verbal, should be provided routinely for patients at diagnosis. cancer 23 
associated thrombosis should be part of standard training and education for all clinicians caring for 24 
people with cancer, including those in primary and palliative care. Recent initiatives such as the  25 
22 
 
International Initiative on Thrombosis and Cancer(55) should help raise awareness and help with 1 
high quality training. Streamlined clinical services for diagnosis and treatment of cancer associated 2 
thrombosis aiming to minimise time in hospital awaiting tests, especially for those with advanced 3 
disease, should improve clinical decision making.(37, 56, 57) 4 
 5 
Conclusion 6 
This systematic review highlights the impact of cancer associated thrombosis on the lives of cancer 7 
patients, and calls for education for patients and clinicians to be part of routine care, and further 8 
work to address this patient priority equal to that of other cancer complications such as spinal cord 9 
compression or neutropenic sepsis. 10 
 11 
Declarations.   12 
Authorship; NB, MJ and AM conceived the research question, NB, MJ developed the search strategy, 13 
NB, MJ, JS and AH contributed to design. NB, WI screened titles and abstracts with recourse to MJ; 14 
NB extracted data and wrote the first draft; All authors interpreted the data and contributed to 15 
drafts and approved the final manuscript  16 
 Funding, This work was conducted as part of a self-funded PhD (NB) 17 
Conflicts of interest: Authors have the following interests to declare: AH, AM and MJ received 18 
funding to complete a qualitative substudy of anticoagulation patient experience funded by BAYER, 19 
JD, WI and NB have nothing to declare.  20 
Ethics and consent: This was not required for this published anonymised evidence synthesis.  21 
Data sharing: Data are available from the published papers in this review 22 
23 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
  8 
24 
 
References 1 
1. Silverstein.MD, Heit.JA, Mohr.DN, Petterson.TM, O’Fallon.WM, Melton.LJ. Trends in the 2 
incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study Arch 3 
Intern Med. 1998;158(6):585-93. 4 
2. White.RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 5 
1):14-8. 6 
3. Blom.JW, Doggen.CJ, Osanto.S, Rosendaal.FR. Malignancies,prothrombotic mutations, and 7 
the risk of venous thrombosis. JAMA. 2005;293:715-22. 8 
4. Heit.JA, Silverstein.MD, Mohr.DN, Petterson.TM, O'Fallon.WM, Melton.LJ. Risk factors for 9 
deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern 10 
Med. 2000;160(6):809-15. 11 
5. Heit.JA, O’Fallon.WM, Petterson.TM, LohseCM, Silverstein.MD, Mohr.D, Melton.LJ. Relative 12 
impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. 13 
Arch Intern Med. 2002;162:1245-8. 14 
6. Donnellan.E, Kevane.B, Healey.B.R, Ainle.FN. Cancer and venous thromboembolic disease: 15 
from molecular mechanisms to clinical management. Current Oncology. 2014;21(3):134-43. 16 
7. Farge.D, Bounameaux.H, Brenner.B, nger.F C, Debourdeau.P, Khorana.AA, Pabinger.I, 17 
Solymoss.S, Douketis.J, Kakkar.A. International clinical practice guidelines including guidance for 18 
direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients 19 
with cancer. Lancet Oncology. 2016;17:e452-66. 20 
8. Venous thromboembolism in adults: diagnosis and management. Quality standard [QS29]: 21 
National Institute for Health and Care Excellence; 2013 [updated 2016]. Available from: 22 
https://www.nice.org.uk/guidance/QS29. 23 
9. Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in 24 
patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol 25 
Pract. 2015;11(3):e442-4. 26 
10. Lee.A.Y.Y, Levine.M.N. Venous Thromboembolism and Cancer: Risks and Outcomes. 27 
Circulation. 2003;107:17-21. 28 
11. Fuente H, Tafur A, Caprini J. Cancer associated thrombosis. Disease-a-Month. 2016;62:121-29 
58. 30 
12. Dentali F, Ageno W, Becattini C, Galli L, Gianni M, Riva N, Imberti D, Squizzato A, Venco A, 31 
Agnelli G. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-32 
analysis. Thromb Res. 2010;125:S166-S91. 33 
13. Noble S, Prout H, Nelson A. Patients' experiences of living with cancer associated thrombosis: 34 
the PELICAN study. Patient preference and adherence. 2015;9:337-45. 35 
14. Korlaa IMv, C.Y.Vossen, F.R.Rosendaal, E.G.Bovill, M.Cushman, S.Naud, A.A.Kaptein. The 36 
impact of venous thrombosis on quality of life. Thromb Res. 2004;114(1):11-8. 37 
15. Hannaa D, White R, T.Wun. Biomolecular markers of cancer-associated thromboembolism. 38 
Critical Reviews in Oncology/Hematology. 2013;88:19-29. 39 
16. Pabinger.I, Thaler.J, Ay.C. Biomarkers for prediction of venous thromboembolism in cancer. 40 
Blood. 2008;122(12):2011-8. 41 
17. Horsted.F, West.J, Grainge.J. Risk of Venous Thromboembolism in Patients with Cancer: A 42 
Systematic Review and Meta-Analysis. PLoS Med. 2012;9(7). 43 
18. Thaler.J, Ay.C, Pabinger.I. Venous thromboembolism in cancer patients – Risk scores and 44 
recent randomised controlled trials. Thromb Haemost. 2012;108:1042-8. 45 
19. Khorana.AA, Connolly.GC. Assessing Risk of Venous Thromboembolism in the Patient With 46 
Cancer. J Clin Oncol. 2009;27(29):4839-47. 47 
20. Lyman.GH. Venous Thromboembolism in the Patient With Cancer. Focus on Burden of 48 
Disease and Benefits of Thromboprophylaxis. American Cancer Society. 2011;117:1334-49. 49 
21. Rodrigues.CA, Ferrarotto.R, Filho.RK, Novis.YAS, Hoff.BMG. Venous thromboembolism and 50 
cancer: A systematic review. Journal of Thrombosis and Thrombolysis. 2010;30(1):67-78. 51 
25 
 
22. Khalil J BB, Elkacemi H, et al. Venous thromboembolism in cancer patients: an 1 
underestimated major health problem. World Journal of Surgical Oncology. 2015;13:204. 2 
23. Shea–Budgell.MA, Wu.CM, Easaw.JC. Evidence-based guidance on venous thromboembolism 3 
in patients with solid tumours. Curr Oncol. 2014;21(3):504-14. 4 
24. Connolly.GC, Khorana.AA. Emerging risk stratification approaches to cancer-associated 5 
thrombosis: risk factors, biomarkers and a risk score. Thrombosis Research. 2010;125(2):S1-S7. 6 
25. CASP, NHS. Critical Appraisal Skills Programme (CASP): appraisal tools. 2003. Available from: 7 
((http://media.wix.com/ugd/dded87_29c5b002d99342f788c6ac670e49f274.pdf). 8 
26. Thomas.J, Harden.A. Methods for the thematic synthesis of qualitative research in 9 
systematic reviews. BMC medical research methodology. 2008;8:45. 10 
27. Boyatzis.RE. Transforming qualitative information: Thematic analysis and code development: 11 
sage; 1998. 12 
28. Barnett-Page.E, Thomas.J. Methods for the synthesis of qualitative research: a critical 13 
review. BMC medical research methodology. 2009;9(1):59. 14 
29. Lucas.PJ, Baird.J, Aria.L, Law.C, Roberts.HM. Worked examples of alternative research in 15 
systematic reviews. BCM Med RES Methodol. 2007;7(4):1471-2288. 16 
30. Mockler.A, O'Brien.B, Emed.J, Ciccotosto.G. The experience of patients with cancer who 17 
develop venous thromboembolism: an exploratory study. Oncology nursing forum. 2012;39(3):E233-18 
40. 19 
31. Seaman S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, 20 
and the patient experience: A qualitative study. Patient Preference and Adherence. 2014;8:453-61. 21 
32. Noble.S, Nelson.A, Fitzmaurice.D, MJ.Bekkers.MJ, Baillie.J, Sivell.S, Canham.J, Smith.J.D, 22 
Casbard.A, Cohen.A, Cohen.D, Evans.J, Fletcher.K, Johnson.M, Maraveyas.A, Prout.H, Hood.K. A 23 
feasibility study to inform the design of a randomised controlled trial to identify the most clinically 24 
effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the 25 
treatment of Cancer-Associated Thrombosis (ALICAT). Health Technol Assess. 2015;19(83). 26 
33. Noble.S, Finlay.IG. Is long-term low-molecular-weight heparin acceptable to palliative care 27 
patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat 28 
Med. 2005;19(3):197-201. 29 
34. Trousseau.A. Phlegmasia alba dolens. In: Clinique Medicale d’Hotel-Dieu de Paris. Paris, 30 
France: JB Balliere et Fils. 1865;3:654-812. 31 
35. Sousou.T, Khorana.AA. Cancer patients and awareness of venous thromboembolism. Cancer 32 
Investigation. 2010;28:44-5. 33 
36. Delluc.A, Carrier.M. Venous thromboembolism in cancer patients:a call for more awareness. 34 
Curr Oncol. 2014;21:163-4. 35 
37. Johnson.MJ, Sheard.L, Maraveyas.A, .S N, Prout.H, Watt.I, Dowding.D. Diagnosis and 36 
management of people with venous thromboembolism and advanced cancer: How do doctors 37 
decide? A qualitative study. BMC Med Inform Decis Mak. 2012;20(12):75. 38 
38. Hunter.R, Lewis.S, Noble.S, Rance.J, Bennett.PD. "Post-thrombotic panic syndrome": A 39 
thematic analysis of the experience of venous thromboembolism. British Journal of Health and 40 
Psychology. 2016. 41 
39. Metastatic spinal cord compression in adults: NICE; 2014. Available from: 42 
https://www.nice.org.uk/guidance/qs56. 43 
40. Neutropenic sepsis: prevention and management in people with cancer: NICE; 2012. 44 
Available from: https://www.nice.org.uk/GUIDANCE/CG151. 45 
41. Fletcher.C. Listening and talking to patients. . BMJ 1980;281:994-6. 46 
42. Noble.S, Lewis.R, Whithers.J, Lewis.S, Bennett.P. Long-term psychological consequencess of 47 
symptomatic pulmonary embolism: a qualitative study. BMJ open. 2014. 48 
43. Rutten.LJ, Arora.NK, Bakos.AD, Aziz.N, Rowland.J. Information needs and sources of 49 
information among cancer patients: a systematic review of research (1980-2003). Patient Education 50 
and Counseling. 2005;57:250-61. 51 
26 
 
44. Moore.T, Norman.P, Harris.P, Makris.M. Cognitive appraisals and psychological distress 1 
following venous thromboembolic disease: An application of the theory of cognitive adaptation. 2 
Social Science and Medicine. 2006;63:1295-406. 3 
45. Etchegary.H, Wilson.B, Brehaut.J, Lott.A, Langlois.N, Wells.PS. Psychosocial aspects of venous 4 
thromboembolic disease: An exploratory study. Thrombosis Research. 2008;122:491-500. 5 
46. Noble.S, Matzdorff.A, Maraveyas.A, Holm.M, Pisa.G. Assessing patients' anticoagulation 6 
preferences for the treatment of cancer-assocaite thrombosis using conjoint methodology. 7 
Heamatologica. 2015;100(11):1486-92. 8 
47. McLean.S, Ryan.K, O’Donnell.JS. Primary thromboprophylaxis in the palliative care setting: a 9 
qualitative systematic review. Palliat Med. 2010;24:386e95. 10 
48. Miller.MW, Nygren.C. Living with cancer-coping behaviors. Cancer Nurs. 1978;1(4):297-302. 11 
49. Diekmann.LM. An evaluation of selected "I Can Cope" programs by registered participants. 12 
Cancer Nurs. 1988;11(5):274-82. 13 
50. Brashers.D.E. Communication and uncertainty management. Journal of Communication. 14 
2001;51:477-97. 15 
51. Brashers.D.E. A theory of communication and uncertainty management. In: Whaley B, 16 
Samter W, editors. Explaining communication theory  Mahwah, NJ: Lawrence Erlbaum Associates; 17 
2007. p. 201-18. 18 
52. Hogan.T.P, Brashers.D.E. The theory of communication and uncertainty management: 19 
Implications from the wider realm of information behavior. In: T.D.Afifi, W.A.Afifi, editors. 20 
Uncertainty, information management, and disclosure decisions: Theories and applications  New 21 
York: NY: Routledge; 2009. p. 45-66. 22 
53. Rains.S.A, Tukachinsky.R. An examination of the relationships among uncertainty, appraisal, 23 
and information-seeking behavior proposed in uncertainty management theory. Health 24 
communication. 2015;30(4):339-49. 25 
54. All Party Parliamentary Group. Venous Thromboembolism (VTE) In Cancer Patients. Cancer, 26 
Chemotherapy and Clots [Report]. 2016. Available from: 27 
https://www.cathrombosis.com/content/type/resources. 28 
55. GFTC, ITAC. International Initiative on Thrombosis and Cancer 2016. Available from: 29 
https://www.itaccme.com/. 30 
56. Sheard.L, Prout.H, Dowding.D, Noble.S, Watt.I, Maraveyas.A, Johnson.MJ. The ethical 31 
decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) 32 
appropriateness of anticoagulation for venous thromboembolism: A qualitative study. BMC Medical 33 
Ethics. 2012;13(1):22. 34 
57. Sheard.L, Prout.H, Dowding.D, Noble.S, Watt.I, Maraveyas.A, Johnson.MJ. Barriers to the 35 
diagnosis and treatment of venous thromboembolism in advanced cancer patients: A qualitative 36 
study. Palliative Medicine. 2012;0(0):1-10. 37 
38 
27 
 
 
Table 1. Overview of the articles included 
Study  Study 
design 
Methods & Sitting Aim Participants characteristics Analysis Principal findings 
N
ob
le
.S
, e
t a
l. 
20
15
.(1
3)
 
PE
LI
CA
N
 
   
   
   
   
   
 Q
ua
lit
at
iv
e 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Semi-structured 
interview. 
 
cancer associated 
thrombosis  clinic 
within regional cancer 
centre and district 
general hospital. 
Cardiff. UK 
Exploring the 
patients 
experiences of  
cancer associated 
thrombosis  within 
the context of 
cancer journey 
N = 20 patients (10 women and 10 
men)  
Age: 53-81 years 
Different primary cancers receiving 
Low molecular weight heparin for 
(2-20 months) 
Fr
am
ew
or
k 
an
al
ys
is 
Diagnosis and treatment of  cancer associated 
thrombosis : 
• Lack of knowledge of venous thromboembolism in 
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• Symptoms of  cancer associated thrombosis  
attributed to cancer or chemotherapy and 
therefore delayed presentation to hospital 
• Initial reaction is shock, little information. 
 Living with  cancer associated thrombosis : 
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cancer associated thrombosis as a setback in cancer 
care:  
• cancer associated thrombosis  symptoms 
preventing a return to normal life after cancer 
treatment  
• cancer associated thrombosis  treatment interfering 
with their cancer care.    
Attitudes about venous thromboembolism treatments:  
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with a sense of obligation. 
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Impact of venous thromboembolism: 
• Symptom burden of  cancer associated thrombosis ,  
• cancer associated thrombosis  in context of cancer,  
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Acceptability of  Low molecular weight heparin :  
• Necessary inconvenience,  
• Systematic approach to injection. 
Hypothetical views on New Oral Anticoagulants: 
• Efficacy paramount,  
• Willing to engage in clinical trials. 
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● The study adds further information on cancer patients’ 
decisions to continue or stop  Low molecular weight 
heparin  treatment is highly influenced by their 
experience of symptomatic venous thromboembolism 
virsus a symptomatic 
•Patients with experience of symptomatic  cancer 
associated thrombosis  were willing and keen to 
continue on Low molecular weight heparin injection as 
long s it takes. 
•Patients who had a symptomatic  cancer associated 
thrombosis  were keen to stop  Low molecular weight 
heparin  injection as soon as possible aiming to have 
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• Acceptability: all patients understood why they are 
on  Low molecular weight heparin  and considered 
it acceptable. 
• Simplicity: the majority found that daily injection of  
Low molecular weight heparin  simpler than the 
frequent INR needed for warfarin. 
• Freedom: many patients expressed a feeling of 
freedom from hospitals, from being restricted to 
their home. 
• Optimism: the feeling that something active being 
done. 
• Bruising: 11 patients described bruising as a 
negative aspect of  Low molecular weight heparin . 
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